Search

News Does the emergence of resistance to cetuximab mean ineffectiveness of all anti-EGFR antibodies?

Colorectal cancer (CRC) cells respond to targeted therapy in different ways. Besides the desired outcome of cell death, CRC cells can adapt and survive through changes in their genome. It is important to recognize that the developed resistance to targeted therapy may, but does not necessarily, apply uniformly across a class of drugs or a single mechanism of action.

Source: Colorectal Cancer 12. 11. 2021

News Clinical Profile and Outcomes of Patients with Cardiac Amyloidosis –⁠ Spanish Experience from Real Practice

Cardiac amyloidosis is caused by the deposition of amyloid fibrils in the myocardium and is among the diseases with significant diagnostic delay. Physicians from the University Hospital in Madrid shared their experiences with the diagnosis and treatment of these patients over the last decade in the cited work below.

Source: Amyloidosis 14. 6. 2023

News Nonacog Beta Pegol (N9-GP) in Bleeding Prophylaxis in Patients with Hemophilia B –⁠ Real World Data

The goal of hemophilia B treatment is currently the prevention of bleeding by administering a coagulation factor IX concentrate. The study presented below brings recent real-world data on treatment outcomes when switching to the latest preparation, nonacog beta pegol (N9-GP).

Source: Hemophilia with Movement 13. 6. 2023

News HVD 2023: Cervical Cancer May Be the First Eliminated Malignancy. What Paths Will Lead to This Goal in the Czech Republic?

Cervical cancer is the 3rd most common cancer among women aged 15–44. Annually, it is diagnosed in 750–800 women in our country, and every 29 hours, one woman dies from it in the Czech Republic. However, it could become the first oncological disease that can be eliminated. How to achieve this was discussed by the chairman of the Czech Vaccinological Society ČLS JEP and Dean of the Faculty of Military Medicine at the University of Defense in Hradec Králové, Prof. MUDr. Roman Chlíbek, Ph.D., at a symposium supported by MSD during the October XVIII. Hradec Vaccinology Days (HVD).

Source: Regular Vaccination 15. 11. 2023

News Comparison of Biologics in the Treatment of Chronic Rhinosinusitis with Nasal Polyps

The authors of a meta-analysis of nine randomized controlled trials comparing dupilumab, omalizumab, and mepolizumab in patients with chronic rhinosinusitis and nasal polyps attempted to identify the most advantageous of the available biologics for this indication based on the ratio of benefits to risks.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 7. 9. 2022

News Efficacy and Safety of Etanercept in the Therapy of Arthritis

A review by experts from Genoa, Italy, focused on the available knowledge regarding the efficacy and safety of etanercept in the treatment of inflammatory rheumatic diseases.

Source: Arthritis 7. 6. 2022

News Fixed Combination of Trastuzumab and Pertuzumab for Subcutaneous Administration in Patients with Early Breast Cancer

At a symposium focused on breast cancer, held in December 2019 in San Antonio, Texas, preliminary results of the FeDeriCa clinical study were presented –⁠ comparing the pharmacokinetics, efficacy, and safety of a fixed combination of trastuzumab and pertuzumab for subcutaneous administration versus intravenous administration in patients with early-stage HER2-positive breast cancer. Based on the presented results, the drug received approval from the U.S. Food and Drug Administration (FDA).

Source: Breast Carcinoma 25. 10. 2020

News Summary of New American Recommendations for Heart Failure Management

This year, the American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA) released joint recommendations for the diagnosis and treatment of heart failure in clinical practice. These new guidelines replace the previous recommendations from 2013 and their 2017 update. We summarize the 10 key points to remember as outlined by the authors of the new guidelines and focus on the treatment of the subgroup of patients with heart failure with preserved ejection fraction (HFpEF).

Source: Heart Failure 28. 6. 2022

News ADCT –⁠ a simple tool for self-diagnosis of patients with severe atopic dermatitis

Atopic dermatitis (AD) is a chronic inflammatory disease not only of childhood. It can negatively affect the quality of life despite being treatable. Control and management of the disease in different areas of life can be easily evaluated using the ADCT questionnaire.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 1. 12. 2020

News Emicizumab Changes the Lifestyle of Patients with Hemophilia A

At the World Federation of Hemophilia (WFH) meeting, data were presented regarding the impact of emicizumab on the lifestyle of people with hemophilia A.

Source: Quality Life Even with Hemophilia 30. 9. 2020

News Cost-effectiveness in Bleeding Control for Acquired Hemophilia A

A pharmacoeconomic analysis showed favorable cost-effectiveness of activated prothrombin complex concentrate in the indication of bleeding control in patients with acquired hemophilia A.

Source: Hemophilia 18. 9. 2020

News Final Analysis of the STASEY Study: How Did Emicizumab Perform in Prophylaxis of Hemophilia A Patients with FVIII Inhibitors?

The July virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021 offered a range of interesting topics. In its poster section, data from the multicenter single-arm open-label phase III clinical trial STASEY, which evaluated the safety and tolerance of emicizumab prophylaxis in patients with hemophilia A and an inhibitor of coagulation factor VIII (FVIII), were presented. Víctor Jiménez-Yuste from La Paz University Hospital in Madrid presented the study results on behalf of the international team of authors.

Source: Quality Life Even with Hemophilia 29. 11. 2021

News Impact of Empagliflozin on the Risk of Cardiovascular Death and Need for Hospitalization Due to Heart Failure

In the EMPA-REG OUTCOME study, empagliflozin reduced the risk of cardiovascular death and the number of hospitalizations due to heart failure in patients with type 2 diabetes (T2DM) who had confirmed cardiovascular disease at study entry. In the following analysis, the authors focused on the benefit of empagliflozin in patients with different levels of risk for heart failure development.

Source: Diabetes 10. 4. 2020

News High Dose of Protein Affects Mortality in Critically Ill Patients if They Do Not Have Sepsis

The optimal composition of nutrition in terms of adequate energy and protein intake for critically ill patients is still a subject of professional discussion. The study cited below aimed to shed more light on this issue by evaluating how early intake of high amounts of proteins and excessive energy intake affects mortality in these patients.

Source: Parenteral Nutrition 28. 5. 2020

News Trifluridine/tipiracil, regorafenib, or supportive therapy? Factors affecting the success of mCRC treatment

Currently, there are no biomarkers available to help decide, for a specific patient with refractory metastatic colorectal cancer (mCRC), whether therapy with trifluridine/tipiracil or regorafenib will be more effective and which patients will benefit the most from the treatment. A group of Czech oncologists presented the results of their analysis on this topic at the Gastrointestinal Symposium of the American Society of Clinical Oncology (ASCO) held in January 2020 in San Francisco.

Source: Treatment of Gastrointestinal Carcinomas 15. 9. 2020